Trump was hosting a news conference to announce a new agreement with drug manufacturers Novo Nordisk and Eli Lilly to broaden access to GLP-1 medications, including Ozempic and Wegovy.
The oral version of the medications is expected to be offered for as low as $149 per month, once approved by the U.S. Food and Drug Administration.
The injectable GLP-1 medications will drop to $245 per month for patients on Medicare or Medicaid who utilize them to treat medical conditions such as diabetes that have already been approved by the FDA.
Bookmark popover
Removed from bookmarks